Connect your AI

Evommune EVMN Derivative Assets Liabilities At Fair Value Net

Derivative Assets Liabilities At Fair Value Net at other companies

Rumble, Inc.RUM

$9.2M—

Columbia Financial, Inc.CLBK

-$3M-173%

Evommune EVMN

$15.37K—

eBayEBAY

$27M-46.0%

Ladder CapitalLADR

$370K-20.8%

Golub CapitalGBDC

$0-100%

Other financials

Income statement

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's derivative assets liabilities at fair value net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evommune 's derivative assets liabilities at fair value net?: Evommune (EVMN) reported derivative assets liabilities at fair value net of $15.37K in Q1 2026.
What does derivative assets liabilities at fair value net mean?: The net fair value of derivative financial instruments held by the company, representing either an asset or a liability position. This metric indicates the company's exposure to market risks, such as interest rate or foreign currency fluctuations, and the effectiveness of its hedging strategies.